ATE385253T1 - Nhibitor-resistente hcv ns3 protease - Google Patents

Nhibitor-resistente hcv ns3 protease

Info

Publication number: ATE385253T1
Authority: AT; Austria
Prior art keywords: protease; resistant; inhibitor; hcv; nhibitor
Prior art date: 2002-10-29

Application number

AT03770808T

Other languages

English (en)

Inventor

George Kukolj

Lisette Lagace

Martin Marquis

Daniel Lamarre

Arnim Pause

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-29

Filing date

2003-10-24

Publication date

2008-02-15

2003-10-24 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2008-02-15 Application granted granted Critical

2008-02-15 Publication of ATE385253T1 publication Critical patent/ATE385253T1/de

Links

108091005804 Peptidases Proteins 0.000 title abstract 3
239000004365 Protease Substances 0.000 title abstract 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 abstract 4
101800001838 Serine protease/helicase NS3 Proteins 0.000 abstract 3
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
238000009877 rendering Methods 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Materials For Photolithography (AREA)
Chemical Or Physical Treatment Of Fibers (AREA)
External Artificial Organs (AREA)

AT03770808T 2002-10-29 2003-10-24 Nhibitor-resistente hcv ns3 protease ATE385253T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42194302P	2002-10-29	2002-10-29

Publications (1)

Publication Number	Publication Date
ATE385253T1 true ATE385253T1 (de)	2008-02-15

Family

ID=32230287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03770808T ATE385253T1 (de)	2002-10-29	2003-10-24	Nhibitor-resistente hcv ns3 protease

Country Status (13)

Country	Link
US (1)	US7208309B2 (de)
EP (1)	EP1558730B1 (de)
JP (1)	JP4295222B2 (de)
AT (1)	ATE385253T1 (de)
AU (1)	AU2003280239B2 (de)
CA (1)	CA2498653C (de)
DE (1)	DE60318954T2 (de)
DK (1)	DK1558730T3 (de)
ES (1)	ES2298585T3 (de)
IL (1)	IL168254A (de)
MX (1)	MXPA05004276A (de)
NZ (1)	NZ540292A (de)
WO (1)	WO2004039970A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005000308A2 (en) *	2003-05-15	2005-01-06	Rigel Pharmaceuticals, Inc.	Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
KR20060120166A (ko) *	2003-10-27	2006-11-24	버텍스 파마슈티칼스 인코포레이티드	Ｈｃｖｎｓ３－ｎｓ４ａ 단백질분해효소 저항성 돌연변이
JP4902361B2 (ja)	2004-01-30	2012-03-21	メディヴィル・アクチエボラーグ	Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
WO2006110762A2 (en) *	2005-04-11	2006-10-19	Achillion	Pharmaceutical compositions for and methods of inhibiting hcv replication
US7465537B2 (en) *	2005-05-01	2008-12-16	The Board Of Trustees Of The University Of Arkansas	Compounds and methods for inhibiting hepatitis C virus replication
US20070128625A1 (en) *	2005-07-25	2007-06-07	Gilead Sciences, Llc	Drug-resistant mutants of hepatitis C virus
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7705138B2 (en)	2005-11-11	2010-04-27	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
EP2392589A3 (de) *	2005-11-11	2012-06-20	Vertex Pharmaceuticals Incorporated	Hepatitis-C-Virusvarianten
EP2527474A1 (de)	2006-10-20	2012-11-28	Innogenetics N.V.	Verfahren zur Analyse von Sequenzvariationen innerhalb des HCV-NS3/4A-Genombereichs
WO2008112108A1 (en) *	2007-03-09	2008-09-18	Merck & Co., Inc.	In vivo hcv resistance to anti-viral inhibitors
WO2008121487A2 (en)	2007-03-29	2008-10-09	The Govt. Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Sevices.	Live attenuated virus vaccines for la crosse virus and other bunyaviridae
WO2010028347A2 (en)	2008-09-05	2010-03-11	President & Fellows Of Harvard College	Continuous directed evolution of proteins and nucleic acids
CA2825370A1 (en)	2010-12-22	2012-06-28	President And Fellows Of Harvard College	Continuous directed evolution
HK1197075A1 (en) *	2011-07-06	2015-01-02	Gilead Sciences, Inc.	Hcv genotype 3 replicons
JP2014522647A (ja)	2011-07-06	2014-09-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｃｖ遺伝子型４レプリコン
WO2015134121A2 (en)	2014-01-20	2015-09-11	President And Fellows Of Harvard College	Negative selection and stringency modulation in continuous evolution systems
WO2016077052A2 (en) *	2014-10-22	2016-05-19	President And Fellows Of Harvard College	Evolution of proteases
WO2016168631A1 (en)	2015-04-17	2016-10-20	President And Fellows Of Harvard College	Vector-based mutagenesis system
WO2017015545A1 (en)	2015-07-22	2017-01-26	President And Fellows Of Harvard College	Evolution of site-specific recombinases
US11524983B2 (en)	2015-07-23	2022-12-13	President And Fellows Of Harvard College	Evolution of Bt toxins
WO2017019895A1 (en)	2015-07-30	2017-02-02	President And Fellows Of Harvard College	Evolution of talens
US11447809B2 (en)	2017-07-06	2022-09-20	President And Fellows Of Harvard College	Evolution of tRNA synthetases
US12060553B2 (en)	2017-08-25	2024-08-13	President And Fellows Of Harvard College	Evolution of BoNT peptidases
WO2019056002A1 (en)	2017-09-18	2019-03-21	President And Fellows Of Harvard College	CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019241649A1 (en)	2018-06-14	2019-12-19	President And Fellows Of Harvard College	Evolution of cytidine deaminases
AU2020252001B2 (en)	2019-03-29	2026-02-26	Trustees Of Boston University	Chimeric antigen receptor (CAR) modulation
US11572565B2 (en)	2020-07-21	2023-02-07	Trustees Of Boston University	Inducible control of gene expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843752A (en) *	1995-05-12	1998-12-01	Schering Corporation	Soluble active hepatitis C virus protease
IT1277914B1 (it) *	1995-08-22	1997-11-12	Angeletti P Ist Richerche Bio	Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
US5990276A (en) *	1996-05-10	1999-11-23	Schering Corporation	Synthetic inhibitors of hepatitis C virus NS3 protease
US6608027B1 (en) *	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6326137B1 (en) *	1999-06-25	2001-12-04	Schering Corporation	Hepatitis C virus protease-dependent chimeric pestivirus
US20050074465A1 (en) *	1999-11-24	2005-04-07	Michael Houghton	HCV fusion proteins with modified NS3 domains
US6986892B1 (en) *	1999-11-24	2006-01-17	Chiron Corporation	Immunogenic Hepatitis C virus non-structural polypeptides
MXPA03005638A (es) *	2000-12-22	2004-04-05	Boehringer Ingelheim Ca Ltd	Auto replicacion de la molecula de arn de virus de la hepatitis c.
WO2002068933A2 (en) *	2001-02-28	2002-09-06	The Scripps Research Institute	Small molecule design against drug resistant mutants using directed evolution
KR20060120166A (ko)	2003-10-27	2006-11-24	버텍스 파마슈티칼스 인코포레이티드	Ｈｃｖｎｓ３－ｎｓ４ａ 단백질분해효소 저항성 돌연변이

2003
- 2003-10-24 CA CA2498653A patent/CA2498653C/en not_active Expired - Lifetime
- 2003-10-24 NZ NZ540292A patent/NZ540292A/en not_active IP Right Cessation
- 2003-10-24 DK DK03770808T patent/DK1558730T3/da active
- 2003-10-24 MX MXPA05004276A patent/MXPA05004276A/es active IP Right Grant
- 2003-10-24 AT AT03770808T patent/ATE385253T1/de active
- 2003-10-24 ES ES03770808T patent/ES2298585T3/es not_active Expired - Lifetime
- 2003-10-24 EP EP03770808A patent/EP1558730B1/de not_active Expired - Lifetime
- 2003-10-24 AU AU2003280239A patent/AU2003280239B2/en not_active Expired
- 2003-10-24 JP JP2004547307A patent/JP4295222B2/ja not_active Expired - Lifetime
- 2003-10-24 WO PCT/CA2003/001636 patent/WO2004039970A1/en not_active Ceased
- 2003-10-24 DE DE60318954T patent/DE60318954T2/de not_active Expired - Lifetime
- 2003-10-28 US US10/695,140 patent/US7208309B2/en not_active Expired - Lifetime
2005
- 2005-04-27 IL IL168254A patent/IL168254A/en unknown

Also Published As

Publication number	Publication date
JP4295222B2 (ja)	2009-07-15
DK1558730T3 (da)	2008-05-26
WO2004039970A1 (en)	2004-05-13
AU2003280239B2 (en)	2009-03-12
EP1558730B1 (de)	2008-01-30
US7208309B2 (en)	2007-04-24
ES2298585T3 (es)	2008-05-16
AU2003280239A1 (en)	2004-05-25
NZ540292A (en)	2006-09-29
IL168254A (en)	2010-11-30
DE60318954D1 (de)	2008-03-20
US20050019753A1 (en)	2005-01-27
JP2006503584A (ja)	2006-02-02
DE60318954T2 (de)	2009-01-22
CA2498653A1 (en)	2004-05-13
EP1558730A1 (de)	2005-08-03
MXPA05004276A (es)	2005-08-03
CA2498653C (en)	2010-12-14

Legal Events

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1558730

Country of ref document: EP

Publication	Publication Date	Title
DK1558730T3 (da)	2008-05-26	Inhibitorresistent HCV-NS3-protease
WO2004101602A3 (en)	2005-06-09	Hepatitis c inhibitor peptide analogs
TW200615275A (en)	2006-05-16	Hepatitis C inhibitor dipeptide analogs
WO2001074768A3 (en)	2002-06-06	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
PL373399A1 (en)	2005-08-22	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
IL162815A0 (en)	2005-11-20	Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2007016476A3 (en)	2008-01-17	Hepatitis c serine protease inhibitors and uses therefor
DE122012000004I1 (de)	2012-04-26	Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
BR0211623A (pt)	2004-07-13	Agentes de contraste alvos multiméricos com base em peptìdeo
ATE547412T1 (de)	2012-03-15	Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
UY27972A1 (es)	2004-04-30	Derivados de hidantoína
EA200400986A1 (ru)	2005-02-24	Гетероциклические трипептиды в качестве ингибиторов вируса гепатита c
CY1109779T1 (el)	2014-09-10	Αναστολεις της hcv ns-3 πρωτεασης σερινης
WO2003064455A3 (en)	2004-02-05	Macrocyclic peptides active against the hepatitis c virus
IL176237A0 (en)	2006-10-05	Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE512971T1 (de)	2011-07-15	Peptidanaloga als hepatitis c-hemmer
TW200508220A (en)	2005-03-01	Hepatitis C inhibitor compounds
SE0201976D0 (sv)	2002-06-24	Novel compounds
IL156774A0 (en)	2004-02-08	Inhibitors of cruzipain and other cysteine proteases
AU2003277891A1 (en)	2004-04-08	Hcv ns-3 serine protease inhibitors
Bennett et al.	2001	The identification of α-ketoamides as potent inhibitors of hepatitis c virus nS3-4a proteinase
WO2003095475A8 (en)	2004-06-10	Peptide compounds and their use as protease substrates
BRPI0416201A (pt)	2006-12-26	métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
ATE125547T1 (de)	1995-08-15	Hiv protease-hemmer.
GB0221169D0 (en)	2002-10-23	Crystal